Healthcare Industry News: ezetimibe/simvastatin
News Release - June 12, 2006
New Study Showed VYTORIN(R) (ezetimibe/simvastatin) Superior to Lipitor in Reducing LDL ''Bad'' Cholesterol in Patients with Type II Diabetes at the Recommended Usual Starting Doses
Source: Merck/Schering-Plough Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.